We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+57.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$886M
Cap. Flow
+$626M
Cap. Flow %
27.61%
Top 10 Hldgs %
43.12%
Holding
273
New
99
Increased
46
Reduced
48
Closed
43

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.4M
3
PRTA icon
Prothena Corp
PRTA
+$14M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
5
PCVX icon
Vaxcyte
PCVX
+$9.67M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$15.3M
2
ETNB
89bio
ETNB
+$7.86M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.57M
4
RPTX
Repare Therapeutics
RPTX
+$5.86M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 23.89%
2 Industrials 0.04%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
126
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$3.12M 0.14%
650,000
+250,000
+63% +$1.26M
CYTK icon
127
CALL
Cytokinetics
CYTK
$10.5B
$3.12M 0.14%
150,000
-1,021,600
-87% -$18.7M
CLVS
128
DELISTED
Clovis Oncology, Inc.
CLVS
$3.08M 0.14%
642,108
-114,128
-15% -$577K
BGMS
129
Bio Green Med Solution Inc
BGMS
$4.91M
$3.06M 0.13%
+109
New +$1.67M
KRRO icon
130
PUT
Korro Bio
KRRO
$150M
$3.03M 0.13%
+1,718
New +$2.27M
AGEN
131
Agenus
AGEN
$312M
$3.02M 0.13%
48,402
– –
ACAD icon
132
Acadia Pharmaceuticals
ACAD
$4.43B
$3M 0.13%
56,008
– –
TRIL
133
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.94M 0.13%
+200,000
New +$2.88M
MRSN
134
DELISTED
Mersana Therapeutics
MRSN
$2.82M 0.12%
+4,240
New +$2.36M
LQDA icon
135
Liquidia Corp
LQDA
$7.48B
$2.81M 0.12%
+951,400
New +$3.49M
ADVM
136
CALL
DELISTED
Adverum Biotechnologies
ADVM
$2.8M 0.12%
25,870
-14,470
-36% -$1.79M
KALV
137
CALL
DELISTED
KalVista Pharmaceuticals
KALV
$2.76M 0.12%
+145,500
New +$2.5M
PSTX
138
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$2.75M 0.12%
250,837
+22,837
+10% +$241K
MDGL icon
139
Madrigal Pharmaceuticals
MDGL
$10.8B
$2.63M 0.12%
23,654
– –
ICAD
140
DELISTED
iCAD Inc
ICAD
$2.58M 0.11%
195,137
+13,800
+8% +$149K
NKTR icon
141
CALL
Nektar Therapeutics
NKTR
$2.39B
$2.55M 0.11%
10,000
– –
CLOV icon
142
CALL
Clover Health Investments
CLOV
$2.2B
$2.52M 0.11%
+150,000
New +$1.67M
ACET icon
143
Adicet Bio
ACET
$85.2M
$2.45M 0.11%
10,892
-6,250
-36% -$1.28M
NUVB icon
144
Nuvation Bio
NUVB
$2.2B
$2.36M 0.1%
+201,808
New +$2.1M
ACHV icon
145
Achieve Life Sciences
ACHV
$659M
$2.3M 0.1%
284,151
– –
NBIX icon
146
CALL
Neurocrine Biosciences
NBIX
$16.8B
$2.27M 0.1%
+23,700
New +$2.29M
KA
147
DELISTED
Kineta, Inc. Common Stock
KA
$2.25M 0.1%
18,931
+1,860
+11% +$283K
AGTC
148
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.23M 0.1%
545,884
– –
SNDX icon
149
CALL
Syndax Pharmaceuticals
SNDX
$1.69B
$2.22M 0.1%
+100,000
New +$2.07M
GWPH
150
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.2M 0.1%
+19,100
New +$2.14M
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Ikarian Capital held 273 positions worth $2.27B, up 64% from $1.38B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $626M of net new capital in Q4 2020, opening 99 new positions and adding to 46 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $15.3M trimmed.

  • Ikarian Capital's largest Q4 2020 buy was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.
  • Ikarian Capital added most to Bristol-Myers Squibb in Q4 2020, an estimated $11.6M increase.
  • Ikarian Capital's biggest Q4 2020 reduction was Ocular Therapeutix, cutting an estimated $15.3M.
  • Ikarian Capital fully exited Repare Therapeutics in Q4 2020, selling an estimated $5.86M.
  • Ikarian Capital's ten largest holdings make up 43% of its $2.27B portfolio in Q4 2020.
  • Ikarian Capital opened 99 new positions and closed 43 in Q4 2020.
  • Ikarian Capital's portfolio value rose 64% quarter-over-quarter to $2.27B.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.